Cases
Bioverativ Inc. (BIVV)
Merger
Overview
Overview
- Date:
- 1/22/2018
- Company Name:
- Bioverativ Inc.
- Stock Symbol:
- BIVV
- Company Name - Buyer:
- Sanofi
- Stock Symbol - Buyer:
- SNY
- Status:
- Closed/Complete
NEW YORK, January 22, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Bioverativ Inc. (NASDAQ: BIVV) stockholders concerning the proposed acquisition of the company by Sanofi (NYSE: SNY).
Our investigation concerns whether Bioverativ’s board of directors failed to adequately shop the company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with Sanofi. Under the terms of the agreement, Bioverativ stockholders will receive $105 per share in cash upon closing of the transaction.
If you own Bioverativ shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
Our investigation concerns whether Bioverativ’s board of directors failed to adequately shop the company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with Sanofi. Under the terms of the agreement, Bioverativ stockholders will receive $105 per share in cash upon closing of the transaction.
If you own Bioverativ shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.